Updates include recommendation to screen for prediabetes and diabetes in all people starting at age 35 years
TUESDAY, Jan. 11, 2022 (HealthDay News) — The Standards of Medical Care in Diabetes clinical practice guideline has been updated for 2022 by the American Diabetes Association and published as a supplement to the January issue of Diabetes Care.
Boris Draznin, M.D., Ph.D., from the University of Colorado Denver, and colleagues on the Professional Practice Committee conducted a systematic review of the literature and graded the scientific evidence to update the Standards of Medical Care in Diabetes.
Updates and additions to the 2022 report include guidance on first-line therapy determined by comorbidities and a recommendation for initiation of screening for prediabetes and diabetes for all people at age 35 years. Changes were made to gestational diabetes mellitus recommendations, including when and who to test. In addition, recommendations were updated on technology selection, based on individual and caregiver considerations, ongoing education relating to device use, continued access to devices across payers, support of student use of devices in schools, use of telehealth, and early initiation of technology.
“The evidence for the prevention and treatment of diabetes and its complications is constantly evolving and it is crucial we do our best to keep medical professionals informed on best practices and medical advances in the field of diabetes,” Robert Gabbay, M.D., Ph.D., chief scientific & medical officer at the American Diabetes Association, said in a statement.
Very Low-Carb Diet Shows Greater Cardiometabolic Benefits Than Other Diets
Time-Restricted Eating May Help Patients With Type 1 Diabetes
Vascular Burden in Midlife Linked to Increased Risk for Dementia, Death
Food-Based Support Aids Type 2 Diabetes Outcomes
GLP-1 Receptor Agonists Tied to Increased Risk for Alopecia
Hypoglossal Nerve Stimulation May Offer Long-Term Cardiovascular Benefits in OSA
Burden of Myocardial Dysfunction Elevated for Individuals With Psoriasis
2017 to 2022 Saw More Than Doubling in Use of GLP-1 Receptor Agonists